17 NOVEMBER NEW ZEALAND GAZETTE 3571

Name and Strength Form Name and Address of Manufacturer Proprietary Name

                                                                                                     (if any)

Melphalan 50 mg Powder for reconstitution Wellcome Foundation Limited, Temple Hill, Alkeran
for iv injection Dartford, Kent, United Kingdom

Calcipotriol 50 mcg/g Topical solution Leo Pharmaceutical Products, Ballerup, Denmark Daivonex Scalp Solution

Alteplase 20 mg, 50 mg Powder for injection Dr Karl Thomae GmbH, Biberach an der Riss, Actilyse
(vial) and diluent Germany

Paclitaxel 30 mg in 5 ml Solution for infusion Bristol-Caribbean Inc., Foreign Trade Zone 7, Taxol Injection
Mayaguez, Puerto Rico

Iloprost trometamol 67 mcg Solution for infusion Schering AG, Berlin, Germany Ilomedin
(equivalent to 50 mcg iloprost) per 0.5 ml solution

Gadopentetic acid, dimeglumine salt Solution for intravenous Schering AG, Wedding Plant, Berlin, Germany Magnevist
469 mg/ml in 5 ml, 10 ml, 15 ml, 20 ml injection

Ramipril 1.25 mg, 2.5 mg, 5 mg, 10 mg Capsules Hoechst AG, Frankfurt (Main), Germany Tritace

• Aciclovir 250 mg Powder for infusion Burroughs Wellcome Co., Greenville, North Carolina, Zovirax IV
United States of America and Wellcome Foundation
Limited, Temple Hill, Dartford, Kent, United Kingdom

Aciclovir 200 mg, 400 mg Tablets Wellcome Australia Limited, Cabarita, New South Zovirax
Wales, Australia

Aciclovir 800 mg Tablet Wellcome Foundation Limited, Temple Hill, Dartford, Zovirax
Kent, United Kingdom

Aciclovir 200 mg/5 ml Oral suspension Wellcome Foundation Limited, Temple Hill, Dartford, Zovirax
Kent, United Kingdom

Aciclovir 200 mg/ 400 mg Tablets Wellcome Australia Limited, Cabarita, New South Zovirax
Wales, Australia

Aciclovir 800 mg Tablet Wellcome Foundation Limited, Temple Hill, Dartford, Zovirax
Kent, United Kingdom

Aciclovir 200 mg/5 ml Oral suspension Wellcome Foundation Limited, Temple Hill, Dartford, Zovirax
Kent, United Kingdom

Dated this 11th day of November 1994.

D. SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.

•

go8293

Mental Health (Compulsory Assessment and Treatment) Act 1992

Section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992

Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, James Christopher Lovelace, Director-General of Health, hereby give notice as follows:

Notice

I. The notice referred to in the Schedule is hereby amended by replacing the words “Allan Lewis Phillips, registered nurse of Rotorua” with the words “Raymond Watson, manager of Rotorua” in the right hand column of the Schedule to the notice specified in the Schedule to this notice.

Schedule

Date of Notice Reference
6 July 1993 New Zealand Gazette, 8 July 1993, No. 103, pages 1959 and 1960.

Dated at Wellington this 14th day of November 1994.

CHRISTOPHER LOVELACE, Director-General.

go8305